Welcome to our dedicated page for Scholar Rock Holding SEC filings (Ticker: SRRK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Scholar Rock Holding Corporation (SRRK) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed biopharmaceutical issuer. Scholar Rock files reports and current updates with the U.S. Securities and Exchange Commission (SEC) that describe its financial condition, clinical and regulatory milestones, capital markets activity, and material corporate events.
For SRRK, Form 8-K current reports are particularly important. Recent 8-K filings have covered quarterly financial and operating results, conference call presentations, and key regulatory developments such as the U.S. Food and Drug Administration’s Complete Response Letter (CRL) for the apitegromab Biologics License Application (BLA) in spinal muscular atrophy (SMA). Other 8-Ks describe the inspection status of a third-party fill-finish facility, the use of an at-the-market equity offering program with Jefferies LLC, and the filing of a prospectus supplement for additional common stock issuance.
Scholar Rock’s filings also document its status as a registrant on The Nasdaq Global Select Market under the ticker SRRK, the terms of its common stock, and its use of a shelf registration statement on Form S-3ASR. Inducement equity awards granted under the company’s 2022 Inducement Equity Plan are reflected in press releases that may be furnished as exhibits to 8-Ks, providing detail on stock options and restricted stock units granted to new employees.
On Stock Titan, users can review these SEC documents alongside AI-powered summaries that explain the main points of each filing in accessible language. Real-time updates from EDGAR help surface new 8-Ks, 10-Q quarterly reports, 10-K annual reports, and any future registration statements or prospectus supplements related to Scholar Rock’s capital-raising activities. For investors analyzing SRRK’s SMA and broader neuromuscular disease programs, these filings offer primary-source insight into clinical progress, regulatory interactions, financing plans, and overall corporate strategy.
Scholar Rock Holding Corp Chief Executive Officer and director David Hallal reported a mandatory share sale linked to equity award vesting. On 01/13/2026, he sold 57,450 shares of common stock at $42.7 per share, solely to cover tax withholding arising from the vesting of performance- and time-based restricted stock units (PSUs) under the company’s equity incentive plans. The transaction was executed as a required “sell to cover” through a designated broker and is noted as not being a discretionary trade.
The vested shares relate to PSU awards granted on April 27, 2025, with 125,000 shares vesting on January 12, 2026, another 125,000 scheduled to vest on April 27, 2027, and additional tranches tied to future stock price and service-based conditions through April 27, 2029, after which any unvested PSUs are forfeited. Following the reported sale, Hallal directly holds 1,541,645 shares of common stock, and a further 205,000 shares are held indirectly by the Hallal Family Irrevocable Trust – 2012, where his spouse serves as trustee and beneficial ownership is disclaimed except for any pecuniary interest.
Scholar Rock Holding Corporation reported preliminary financial and business updates, including an estimated unaudited cash, cash equivalents and marketable securities balance of approximately $365 million as of December 31, 2025. The company has not yet finalized its full fourth-quarter and full-year 2025 results, and the ongoing audit could change these preliminary figures.
The company also issued a press release with business updates and more detail on its 2026 strategic priorities, furnished as Exhibit 99.1, and prepared a corporate presentation for meetings at the 44th Annual J.P. Morgan Healthcare Conference, filed as Exhibit 99.2. The update includes forward-looking statements about its growth strategy, clinical programs, regulatory timelines, commercial launch expectations, a cash runway into 2027, and other operational milestones, all subject to risks outlined in its most recent quarterly report.
Scholar Rock Holding Corp director reports tax-related stock sales. A company director filed a Form 4 for two sales of common stock on 12/16/2025. The director sold 726 shares at a weighted average price of $43.8761, with individual trade prices ranging from $43.39 to $44.38. A second sale covered 280 shares at a weighted average price of $44.6344, with prices ranging from $44.39 to $45.23. These transactions were executed under a Rule 10b5-1 trading plan adopted on November 20, 2024 to cover tax obligations upon the vesting and settlement of restricted stock units. Following the transactions, the director beneficially owns 32,908 equity awards, consisting of 14,844 shares of common stock and 18,064 restricted stock units (RSUs), all held directly.
Scholar Rock Holding Corp director Srinivas Akkaraju reported multiple transactions in the company’s common stock. On 10/07/2025, he indirectly purchased 12,796, 12,400 and 4,403 shares through Samsara Opportunity Fund, L.P. at weighted average prices of $39.31, $40.18 and $40.97 per share, increasing that fund’s indirect holdings to 530,038 shares.
On 12/12/2025, warrants with a $7.35 exercise price were exercised through Samsara BioCapital, L.P., resulting in the acquisition of 1,064,804 shares of common stock and raising that entity’s indirect holdings to 6,367,614 shares, with the related warrant position reduced to zero. The form also shows 21,132 shares of common stock held directly. Footnotes explain that the 10/07/2025 purchase prices are weighted averages for multiple trades within specified price ranges.
Scholar Rock Holding Corporation announced it filed a prospectus supplement for its at-the-market offering program, permitting the offer and sale, from time to time at its sole discretion, of additional shares of common stock with an aggregate offering price of up to $200,000,000. Sales will be conducted through Jefferies LLC as sales agent under the company’s automatically effective shelf registration statement on Form S-3ASR.
Offerings of these shares will be made only by means of the prospectus supplement and the base prospectus. The company also filed a legal opinion from Goodwin Procter LLP as an exhibit. This update provides ongoing access to equity capital via an established ATM facility, allowing the company to sell small amounts of stock into the market as conditions permit.
Scholar Rock Holding Corporation launched an at‑the‑market offering of its common stock, allowing sales of up to $200,000,000 from time to time through Jefferies LLC acting as agent. Sales, if any, will be made pursuant to Rule 415(a)(4) and Jefferies will use commercially reasonable efforts; there is no obligation to sell a minimum amount.
Jefferies will receive up to 3.0% of gross proceeds as commissions and will be deemed an underwriter. Net proceeds are intended to support commercialization of apitegromab, advance clinical programs and the platform, and for working capital and general corporate purposes. SRRK is listed on Nasdaq; the common stock last closed at $30.82 on November 12, 2025. Shares outstanding were 99,171,486 as of September 30, 2025; this is a baseline figure, not the amount being offered.
Scholar Rock (SRRK) reported Q3 2025 results with a larger loss as it prepares for potential commercialization. Net loss was $102.2 million for the quarter and $287.0 million for the nine months. Operating expenses rose to $103.6 million in Q3, driven by higher R&D to support apitegromab and pipeline work, and sharply higher G&A for launch readiness, equity-based comp, and professional services.
Liquidity remains solid. Cash, cash equivalents and marketable securities totaled $369.6 million as of September 30, 2025, with long‑term debt of $99.6 million. The company raised $91.7 million net through its ATM in 2025 (2,767,000 shares) and drew an additional $50.0 million term loan on September 29, bringing total term loans funded to $100.0 million. Shares outstanding were 102,007,457 as of November 5, 2025.
Regulatory update: The FDA issued a Complete Response Letter in September tied to site‑related observations at a third‑party fill‑finish facility; no efficacy or safety issues were cited. Scholar Rock held a Type A meeting in November and plans to resubmit the apitegromab BLA when the facility is reclassified. The EMA validated the apitegromab MAA in March 2025.
Scholar Rock Holding Corporation (SRRK) furnished an update regarding its quarterly results process. The company issued a press release with financial and operating results for the quarter ended September 30, 2025, furnished as Exhibit 99.1.
It also furnished presentation slides as Exhibit 99.2 for a conference call scheduled for 8:00 am ET on November 14, 2025. The press release and slides are furnished, not filed, under the Exchange Act.
Scholar Rock (SRRK) reported an update under Other Events. On October 10, 2025, the company was informed by Novo Nordisk that the U.S. Food and Drug Administration has classified the Catalent Indiana, LLC facility as “official action indicated.”
The classification follows a Form FDA 483 issued to Catalent Indiana, LLC on July 14, 2025. The filing does not provide additional details or actions beyond noting the FDA’s inspection outcome.
David Hallal, who serves as Chief Executive Officer and a Director of Scholar Rock Holding Corp (SRRK), transferred 205,000 shares of the issuer's common stock to the Hallal Family Irrevocable Trust - 2012 on
After the reported transfer, the filing shows the reporting person beneficially owns 1,599,095 shares, consisting of 99,095 shares of common stock and 1,500,000 restricted stock units. The statement was signed by an attorney-in-fact on
FAQ
What is the current stock price of Scholar Rock Holding (SRRK)?
What is the market cap of Scholar Rock Holding (SRRK)?
